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IFN-g-activated macrophages attempt to limit pathogen growth through tryptophan starvation.
Zhang et al. demonstrate thatMycobacterium tuberculosis responds to this threat by synthesizing
its own tryptophan. Genetic and chemical inhibition of this pathway reducesmycobacterial survival,
revealing a new immune-dependent drug target for tuberculosis.The portfolio of drugs available for treat-
ment of tuberculosis is limited, and ther-
apy is fraught with problems linked to
the need for prolonged use of multiple an-
tibiotics and the constant emergence of
drug resistance, which highlights the ne-
cessity for replenishing the drug discov-
ery pipeline with new targets. In this issue,
Zhang et al. (2013) report the identification
of a new ‘‘cryptic’’ drug target that only
becomes apparent in the context of the
host immune response to the pathogen.
The authors employed an unbiased ge-
netic screen using a transposon insertion
site-mapping method (TraSH) to identify
bacterial genes that are specifically
required for survival of Mycobacterium
tuberculosis (Mtb) in the presence of an
intact immune response. Deep-sequence
mapping of the insertion sites in the input
and output mutant pools facilitated identi-
fication of thosemutants that are selected
against in immunocompetent mice, but
not in MHC class-II-deficient animals,
which lack the CD4 T cell compartment
that is important to fight mycobacterial
infections. This set of genes is defined
as the CD4 ‘‘counteractome,’’ or the
genes required specifically for coping
with the immune environment generated
by CD4 T cells.
Genes involved in both gluconeogen-
esis and tryptophan biosynthesis are
highly selected against only in immuno-
competent mice, indicating that the
immune environment impacts bacterial
metabolism. The authors demonstrate
that depletion of tryptophan in the host
cells, through immune-mediated upregu-
lation of expression of host indoleamine
2,3-dioxygenase (IDO-1), stimulates intra-
cellular Mtb to synthesize their own
tryptophan (Figure 1A). IDO-1 is therate-limiting enzyme in tryptophan break-
down in host macrophages. Analysis of
a Mtb mutant deficient in trpE, which
encodes the enzyme that converts
chorismate to anthranilate as the first
committed step in tryptophan biosyn-
thesis, shows that the resulting trypto-
phan auxotroph dies in the absence of
exogenous tryptophan. Consistent with
the in vivo infection data, the phenotype
of the trpE mutant is enhanced greatly in
macrophages activated with interferon-g
(IFN-g), which increases IDO-1 produc-
tion in the host cells.
Recent reports on IDO-1 have tended
to focus on the role of the enzyme in im-
mune regulation through reducing T cell
proliferation and modulating regulatory
T cell responses in a variety of disease
models. However, much earlier studies
reported that IDO-1 induced by IFN-g
blocks the growth of Toxoplasma gondii
in human fibroblasts through the degra-
dation of tryptophan (Pfefferkorn, 1984;
Pfefferkorn et al., 1986). Since this initial
observation, tryptophan starvation has
been shown to represent an antimicrobial
response that is important for the restric-
tion of intracellular infections, including
Chlamydia and Leishmania (Murray et al.,
1989; Nelson et al., 2005). The demon-
stration that Mtb relies on its own trypto-
phan synthesis pathway to compensate
for this host defense response explains
why no phenotype was observed when
IDO-1-deficient mice were infected
with wild-type Mtb (Blumenthal et al.,
2012). Other pathogens also have the
ability to synthesize tryptophan, including
Streptococcus pneumonia and Legionella
pneumophila. In a recent study, Peng and
Monack performed a transposon inser-
tion site-mapping screen on a panel ofCell 155, DFrancisella tularensis mutants to identify
genes that are required for survival in the
mouse lung (Peng and Monack, 2010)
and found that insertional disruption of
trpA and trpB, which encode a tetrameric
a2b2 tryptophan synthase gene, yields
a severely attenuated phenotype. On
analysis of lung, liver, and spleen, they
found that expression of IDO-1 is
much higher in the lung and that IDO-1-
dependent containment of the bacterial
infection is much more effective in this
organ compared to infection via alternate
routes, providing further evidence that
manipulation of tryptophan metabolism
impacts microbial growth.
Finally, what makes the current study
particular noteworthy are the experi-
ments utilizing inhibitors of bacterial tryp-
tophan synthesis to validate conditionally
essential gene products as potential
drug targets. They found that fluorinated
anthranilate derivatives 5-FABA and
6-FABA block tryptophan synthesis in
Mtb through inhibition of TrpE activity
and are bactericidal in the absence of ex-
ogenous tryptophan. Both compounds
enhanced IFN-g-induced killing of intra-
cellular bacteria in macrophage infections
in vitro and also showed activity in vivo in
infected wild-type mice. These data pro-
vide proof of principle that the metabolic
pathways required by Mtb for survival in
an immunocompetent host can be ex-
ploited as potential targets for therapy.
Similar cryptic potential drug targets had
been reported previously. For instance,
isocitrate lyase, which is required for
both gluconeogenesis and the detoxifica-
tion of propionyl-CoA generated predom-
inantly through the catabolism of choles-
terol, is necessary to sustain infection in
wild-type mice, but not in IFN-g-deficientecember 5, 2013 ª2013 Elsevier Inc. 1209
Figure 1. Cryptic Weaknesses in the Armor of Mycobacterium tuberculosis Are Revealed
under Immune Pressure
(A) Activation of macrophages by IFN-g results in upregulation of coregulated genes with promoters that
contain interferon-sensitive response elements (ISREs). One of these genes, Ido-1, encodes an indole-
amine 2,3-dioxygenase that degrades cytosolic tryptophan, reducing the availability of this amino acid to
intracellularMycobacterium tuberculosis (Mtb). Under the resulting tryptophan deprivation, Mtb activates
its own tryptophan synthesis enzymes to produce tryptophan and circumvent this pathway of immune-
mediated control, revealing a potential drug target that would enhance the ability of the host immune
system to eliminate the pathogen.
(B) In addition to tryptophan deprivation, other environmental stresses are enhanced by immune activation
and could be explored as routes to revealing other immune-dependent drug targets. These range from
intravacuolar pH through production of reactive nitrogen and oxygen radials and the acquisition of lyso-
somal hydrolases to restriction of the range of nutrients available to the pathogen.mice (Lee et al., 2013; McKinney et al.,
2000). Also, a functional proteasome is
required whenMtb is exposed to nitric ox-
ide intermediates produced by activated
murine macrophages. Mutants lacking
proteasome subunits exhibit reduced
virulence that is recovered partially in
iNOS-deficient mice (Darwin et al., 2003).
Other immune-mediated environmental
stresses could be explored to reveal addi-
tional drug targets that exploit the path-
ways that Mtb activates in response to
host-derived pressure (Figure 1B). How-
ever, sensitivity to such compounds will
depend on the local immune environment,1210 Cell 155, December 5, 2013 ª2013 Elsewhich is heterogeneous within tubercu-
losis granulomas, and therefore drug
pressure will by definition vary in intensity
within each lesion. Will such a scenario
accelerate the rate of development of
drug resistance? Existing drugs preferen-
tially target replicating organisms, and
nonreplicating bacteria exhibit an innate
resistance to their activities. Thus, the
most attractive new drug targets would
be those that fulfill the housekeeping
functions required to maintain bacterial
homeostasis. Theoretically, such targets
would not be replication dependent and
are likely to be subject to increased pres-vier Inc.sure under immune stresses (Figure 1B).
Compounds that target pathways
induced or enhanced by immune-medi-
ated stress, if used in combination with
existing therapies, could increase treat-
ment efficacy by increasing coverage of
the heterogeneous bacterial population.
Therefore, the identification of condition-
ally dependent targets of drug action,
such as the one reported by Zhang and
colleagues, represents a significant con-
ceptual shift toward a more holistic drug
discovery program for anti-infectives
that incorporates and exploits the contri-
bution of the host.
REFERENCES
Blumenthal, A., Nagalingam, G., Huch, J.H.,
Walker, L., Guillemin, G.J., Smythe, G.A., Ehrt, S.,
Britton, W.J., and Saunders, B.M. (2012). PLoS
ONE 7, e37314.
Darwin, K.H., Ehrt, S., Gutierrez-Ramos, J.C.,
Weich, N., and Nathan, C.F. (2003). Science 302,
1963–1966.
Lee, W., VanderVen, B.C., Fahey, R.J., and Rus-
sell, D.G. (2013). J. Biol. Chem. 288, 6788–6800.
McKinney, J.D., Ho¨ner zu Bentrup, K., Mun˜oz-
Elı´as, E.J., Miczak, A., Chen, B., Chan,W.T., Swen-
son, D., Sacchettini, J.C., Jacobs, W.R., Jr., and
Russell, D.G. (2000). Nature 406, 735–738.
Murray, H.W., Szuro-Sudol, A., Wellner, D., Oca,
M.J., Granger, A.M., Libby, D.M., Rothermel,
C.D., and Rubin, B.Y. (1989). Infect. Immun. 57,
845–849.
Nelson, D.E., Virok, D.P., Wood, H., Roshick, C.,
Johnson, R.M., Whitmire, W.M., Crane, D.D.,
Steele-Mortimer, O., Kari, L., McClarty, G., and
Caldwell, H.D. (2005). Proc. Natl. Acad. Sci. USA
102, 10658–10663.
Peng, K., and Monack, D.M. (2010). Infect. Immun.
78, 2723–2733.
Pfefferkorn, E.R. (1984). Proc. Natl. Acad. Sci. USA
81, 908–912.
Pfefferkorn, E.R., Rebhun, S., and Eckel, M. (1986).
J. Interferon Res. 6, 267–279.
Zhang, Y.J., Reddy, M.C., Ioerger, T.R., Rothchild,
A.C., Dartois, V., Schuster, B.M., Trauner, A.,
Wallis, D., Galaviz, S., Huttenhower, C., et al.
(2013). Cell 155, this issue, 1296–1308.
